New data for St Jude Medical’s devices and technologies will be presented during late-breaking clinical trial presentations at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) symposium (29 October–2 November, Washington, DC, USA). At press release reports that throughout the congress, the company will also feature its latest cardiovascular innovations—including PressureWire X guidewire, structural heart solutions and the CardioMEMS heart failure system—that demonstrate its commitment to transforming the treatment of cardiovascular disease.
According to the press release, three late-breaking trials/first report investigations sessions will highlight data from St Jude Medical advancements in vascular and structural heart technologies. They are:
A comparison of stent visualisation technologies for use during percutaneous coronary intervention (PCI)—data from the first randomised clinical trial to compare OCT-guided, IVUS-guided and angiography-guided PCI; 30 October, 9am (late-breaking trials session)
Final long-term results from the RESPECT trial, comparing recurrent stroke in patients with the Amplatzer patent foramen ovale closure to contemporary medical management; 1 November, 12.15pm (first report investigations sessions)
Initial data from the largest, prospective evaluation of the Amplatzer Amulet left atrial appendage occluder device, designed to seal the left atrial appendage to prevent stroke in patients with non-valvular atrial fibrillation; 2 November, 9.40am (late-breaking trials session);
According to the press release, leading interventional cardiologists will also be on hand to demonstrate the Optis integrated system from 10am to 11am and from 2pm to 3pm each day during exhibit hours (30 October–1 November). Additionally, 31 October, St Jude Medical is sponsoring a TCT satellite symposium, “Interventional management of complex patients, cutting edge technologies for the advanced interventionalist.” For more information about this event, click here
